Drug intelligence / Profile preview

Univ. of Alberta NEU3 compound 963

Development stage: Unknown
Lead developer: University of Alberta

Overview

Univ. of Alberta NEU3 compound 963: sourced facts only. name: "Within this library, we identified a C9 biphenyl carbamate derivative (963) that showed high selectivity and potency for NEU3 (Ki = 0.12 ± 0.01 μM)." [PMID:39101748]; target: "Within this library, we identified a C9 biphenyl carbamate derivative (963) that showed high selectivity and potency for NEU3 (Ki = 0.12 ± 0.01 μM)." [PMID:39101748]; developer: "Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada." [PMID:39101748]

Targets

NEU3 (Neuraminidase 3)

Beyond the preview

Go deeper on Univ. of Alberta NEU3 compound 963.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Univ. of Alberta NEU3 compound 963.